The Dietary Supplement cGMP rule (21 CFR part 111)

Attend this 60-minute presentation to gain a fundamental understanding of the FDA's regulation of dietary supplements and dietary supplement marketing, manufacturing, labeling, and advertising, all of which are regulated and enforced by the FDA and the Federal Trade Commission.

Thomas E. Colonna
Thomas E. Colonna
Tuesday, March 31, 2020
10:00 AM PDT | 01:00 PM EDT
60 Minutes

More Trainings by this Expert   Product Id : 502929

Price Details
$150 Live
$290 Corporate Live
$190 Recorded
$390 Corporate Recorded
Combo Offers
Live + Recorded
$289 $340 Live + Recorded
Corporate (Live + Recorded)
$599 $680 Corporate
(Live + Recorded)
Price Detail Options

FDA regulates both finished dietary supplement products and dietary ingredients.

FDA regulates dietary supplements under a different set of regulations than those covering "conventional" foods and drug products.
Under the Dietary Supplement Health and Education Act of 1994 (DSHEA):

  • Manufacturers and distributors of dietary supplements and dietary ingredients are prohibited from marketing products that are adulterated or misbranded.
    That means that these firms are responsible for evaluating the safety and labeling of their products before marketing to ensure that they meet all the requirements of DSHEA and FDA regulations.
  • FDA is responsible for taking action against anyadulterated or misbranded dietary supplement product after it reaches the market

Why should you Attend: To gain a fundamental understanding of dietary supplement cGMPs.

Areas Covered in the Session:
  • Definition of Dietary Supplement
  • Current Good Manufacturing Practices

Who Will Benefit:
  • Regulatory Professionals Working in the Field of Dietary Supplements

Speaker Profile
Thomas E. Colonna earned a bachelor of science in microbiology from the University of Sciences in Philadelphia (formerly the Philadelphia College of Pharmacy and Science), a Ph.D. in molecular biology from the Johns Hopkins University, and a law degree from the Georgetown University Law Center. In addition, Dr. Colonna holds academic appointments at Johns Hopkins University and the University of Sciences in Philadelphia.

Dr. Colonna provides consulting services in the scientific and regulatory aspects of a wide range of medical devices and biologics with particular expertise in the areas of in vitro diagnostics (ELISA-based, PCR-based, SNPs, microarrays, and pharmacogenomics), medical device software (including bioinformatics), and biotechnology-based products.

Dr. Colonna's consulting clients range from Fortune 500 companies to small start-up companies located throughout the US, as well as, Canada, India, and Russia. Widely published in numerous fields, Dr. Colonna brings a unique multidisciplinary approach to problem solving.

You Recently Viewed